GOLDEN, Colo. — April 17, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Vaccibody AS has received approval to start their cancer neoantigen trial using the PharmaJet Stratis® needle-free injection system.
DetailsGOLDEN, Colo. — March 27, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced plans to present their latest research results at the World Vaccine Congress on April 5, in Washington DC at the Renaissance Washington DC Downtown Hotel. The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, will be presented by Dr. Erin Spiegel, Director of Scientific Affairs at PharmaJet, Inc.
DetailsGOLDEN, Colo. — March 13, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced the reporting of positive interim results from the Phase 1 clinical trial conducted by the US Army Medical Research Institute of Infectious Diseases (USAMRIID). The clinical trial is evaluating two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS), using the PharmaJet Stratis® needle-free injection system.
DetailsGOLDEN, Colo. — Feb. 20, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced a global license agreement with Genexine, a leading biotherapeutics company headquartered in South Korea, for the development and commercialization of DNA vaccines for human applications using the PharmaJet needle-free injection systems.
DetailsGOLDEN, Colo. — Feb. 6, 2018 — PharmaJet, the maker of innovative, needle-free injection technology, today announced that Vaccibody AS is expanding their human clinical trial (phase IIa) for the study of a vaccine to treat HPV disease using the PharmaJet Stratis® needle-free injection system.
DetailsGOLDEN, Colo. — Jan. 23, 2018 — PharmaJet® Inc., the maker of innovative, needle-free injection technology, announced that a study was published in Heliyon Journal showing PharmaJet needle-free injection is superior to needle and syringe for fractional dose poliovirus vaccine campaigns.
DetailsGOLDEN, Colo. — Jan. 9, 2018 — PharmaJet, the maker of innovative, needle-free injection technology announced that a recently published study in The Lancet demonstrated that delivery of a Zika virus vaccine with the PharmaJet Stratis® Needle-free Jet injector produced a significantly higher immune response, as compared with administration via needle and syringe.
DetailsGOLDEN, Colo. — Dec. 19, 2017 — PharmaJet, the maker of innovative, needle-free injection technology, announced that Invectys, a French-based biopharmaceutical company, received US FDA approval to proceed with a phase II clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system.
DetailsGOLDEN, Colo. – Dec. 5, 2017 – PharmaJet® Inc., the maker of needle-free injection technology, announced today that the first ever human clinical study of an mRNA rabies vaccine successfully showed immunogenicity when administered with their needle-free injection devices.
DetailsGOLDEN, Colo. – Aug. 29, 2017 – PharmaJet® Inc., the maker of needle-free injection technology, today announced that shipping has begun for the quadrivalent influenza vaccine for needle-free delivery with the PharmaJet Stratis® device for the 2017-18 influenza season.
Details
